Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
This cross-sectional retrospective pilot study assessed cerebrospinal fluid neurofilament light on patients referred to a tertiary neuropsychiatry service from 2009 to 2017 for diagnostic assessment of neuropsychiatric and neurocognitive symptoms, where a neurodegenerative disorder was a differential diagnosis, who received lumbar punctures as part of a comprehensive workup.
|
31220922 |
2020 |
Neurodegenerative Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We aimed to discover single nucleotide polymorphisms (SNPs) associated with longitudinal changes in plasma NFL levels that affect the risk of developing neurodegenerative disease and clinical disease progression.
|
31295725 |
2019 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Blood markers indicative of neurodegeneration (neurofilament light chain; NFL), Alzheimer's disease amyloid pathology (amyloid-β; Aβ), and neuroinflammation (kynurenine pathway; KP metabolites) have been investigated independently in neurodegenerative diseases.
|
31601232 |
2019 |
Neurodegenerative Disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this case-control study, we investigated NFL levels in CSF obtained from controls and patients with several neurodegenerative diseases.
|
30508027 |
2019 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Neurofilament light chain (NfL) was recently proposed as a serum biomarker for many neurodegenerative disorders.
|
31684998 |
2019 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Neurofilament Light Chain in Cerebrospinal Fluid and Blood as a Biomarker for Neurodegenerative Diseases: A Systematic Review and Meta-Analysis.
|
31744001 |
2019 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Neurofilament light chain (NEFL), a subunit of neurofilament, has been shown to play an important role in pathogenic neurodegenerative disease and in radial axonal growth.
|
30569449 |
2019 |
Neurodegenerative Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We produced two monoclonal antibodies (NfL21 and NfL23) directed against the NfL core domain, and developed a novel sandwich ELISA method that we evaluated in patients with: 1) inflammatory demyelinating diseases (IDD; n = 97), including multiple sclerosis (MS; n = 59), clinically isolated syndrome (CIS; n = 32), and radiologically isolated syndrome (RIS; n = 6); 2) Alzheimer's disease (AD; n = 72), including mild cognitive impairment due to AD (MCI-AD, n = 36) and probable AD dementia (AD-dem; n = 36); 3) Parkinson's disease (PD; n = 30); and 4) other neurological noninflammatory and non-neurodegenerative diseases (OND; n = 30).
|
29370869 |
2018 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Neurofilament light chain (NfL) is a promising biomarker in neurodegenerative diseases.
|
29937097 |
2018 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Objectives:</b> Elevated neurofilament light chain (NFL) levels within the cerebrospinal fluid (CSF) are a biomarker representing axonal neurodegeneration in rapid progressive neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).
|
30631300 |
2018 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Background:</b> Neurofilament light chain (NfL) is a highly promising biomarker of neuroaxonal injury that has mainly been studied in adult neurodegenerative disease.
|
30524361 |
2018 |
Neurodegenerative Disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The levels of CSF NF-L detected in p25 mice are about 4-fold higher than the CSF levels detected in patients with chronic neurodegenerative diseases, such as symptomatic FTD (bvFTD).
|
28392472 |
2017 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Neurofilament light chain (NfL) has a significant role in distinguishing PD from other neurodegenerative diseases.
|
26991855 |
2017 |